enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

3. AstraZeneca diabetes drug gets U.S. nod to treat heart failure

   www.aol.com/news/astrazenecas-diabetes-drug-gets...

   The U.S. Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular death and hospitalisation for heart failure in certain patients, regardless of their diabetes ...

4. AstraZeneca's Farxiga cuts death risk in heart failure ... - AOL

   www.aol.com/news/astrazenecas-farxiga-cuts-death...

   AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released ...

5. Dapagliflozin - Wikipedia

   en.wikipedia.org/wiki/Dapagliflozin

   Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [6] [7] [10] It is also used to treat adults with heart failure and chronic kidney disease.

6. Canagliflozin - Wikipedia

   en.wikipedia.org/wiki/Canagliflozin

   Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...

7. Thiazolidinedione - Wikipedia

   en.wikipedia.org/wiki/Thiazolidinedione

   Thiazolidinedione ligand dependent transactivation is responsible for the majority of anti-diabetic effects. The activated PPAR/RXR heterodimer binds to peroxisome proliferator hormone response elements upstream of target genes in complex with a number of coactivators such as nuclear receptor coactivator 1 and CREB binding protein, this causes upregulation of genes (for a full list see PPARγ):